Developing standardized corticosteroid treatment for Duchenne muscular dystrophy

Michela Guglieri, Kate Bushby, Michael P. McDermott, Kimberly A. Hart, Rabi Tawil, William B. Martens, Barbara E. Herr, Elaine McColl, Jennifer Wilkinson, Janbernd Kirschner, Wendy M. King, Michele Eagle, Mary W. Brown, Tracey Willis, Deborah Hirtz, Perry B. Shieh, Volker Straub, Anne Marie Childs, Emma Ciafaloni, Russell J. ButterfieldIain Horrocks, Stefan Spinty, Kevin M. Flanigan, Nancy L. Kuntz, Giovanni Baranello, Helen Roper, Leslie Morrison, Jean K. Mah, Adnan Y. Manzur, Craig M McDonald, Ulrike Schara, Maja von der Hagen, Richard J. Barohn, Craig Campbell, Basil T. Darras, Richard S. Finkel, Giuseppe Vita, Imelda Hughes, Tiziana Mongini, Elena Pegoraro, Matthew Wicklund, Ekkehard Wilichowski, W. Bryan Burnette, James F. Howard, Hugh J. McMillan, Mathula Thangarajh, Robert C. Griggs

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Despite corticosteroids being the only treatment documented to improve strength and function in boys with Duchenne muscular dystrophy (DMD) corticosteroid prescription is inconsistent and in some countries, corticosteroids are not prescribed. We are conducting a clinical trial that (1) compares the 3 most frequently prescribed corticosteroid regimes; (2) standardizes treatment of DMD complications; and (3) standardizes prevention of corticosteroid side effects. Investigators at 38 sites in 5 countries plan to recruit 300 boys aged 4–7 who are randomly assigned to one of three regimens: daily prednisone; daily deflazacort; or intermittent prednisone (10 days on/10 days off). Boys are followed for a minimum of 3 years to assess the relative effectiveness and adverse event profiles of the different regimens. The primary outcome is a 3-dimensional variable consisting of log-transformed time to rise from the floor, forced vital capacity, and subject/parent satisfaction with treatment, each averaged over all post-baseline visits. The study protocol includes evidence- and consensus-based treatment of DMD complications and of corticosteroid side effects. This study seeks to establish a standard corticosteroid regimen for DMD. Since all new interventions for DMD are being developed as add-on therapies to corticosteroids, defining the optimum regimen is of importance for all new treatments.

Original languageEnglish (US)
Pages (from-to)34-39
Number of pages6
JournalContemporary Clinical Trials
Volume58
DOIs
StatePublished - Jul 1 2017

Fingerprint

Duchenne Muscular Dystrophy
Adrenal Cortex Hormones
Therapeutics
Prednisone
Vital Capacity
Prescriptions
Consensus
Research Personnel
Clinical Trials

Keywords

  • Deflazacort
  • Duchenne muscular dystrophy
  • Prednisolone
  • Randomized
  • Standards of care

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology (medical)

Cite this

Guglieri, M., Bushby, K., McDermott, M. P., Hart, K. A., Tawil, R., Martens, W. B., ... Griggs, R. C. (2017). Developing standardized corticosteroid treatment for Duchenne muscular dystrophy. Contemporary Clinical Trials, 58, 34-39. https://doi.org/10.1016/j.cct.2017.04.008

Developing standardized corticosteroid treatment for Duchenne muscular dystrophy. / Guglieri, Michela; Bushby, Kate; McDermott, Michael P.; Hart, Kimberly A.; Tawil, Rabi; Martens, William B.; Herr, Barbara E.; McColl, Elaine; Wilkinson, Jennifer; Kirschner, Janbernd; King, Wendy M.; Eagle, Michele; Brown, Mary W.; Willis, Tracey; Hirtz, Deborah; Shieh, Perry B.; Straub, Volker; Childs, Anne Marie; Ciafaloni, Emma; Butterfield, Russell J.; Horrocks, Iain; Spinty, Stefan; Flanigan, Kevin M.; Kuntz, Nancy L.; Baranello, Giovanni; Roper, Helen; Morrison, Leslie; Mah, Jean K.; Manzur, Adnan Y.; McDonald, Craig M; Schara, Ulrike; von der Hagen, Maja; Barohn, Richard J.; Campbell, Craig; Darras, Basil T.; Finkel, Richard S.; Vita, Giuseppe; Hughes, Imelda; Mongini, Tiziana; Pegoraro, Elena; Wicklund, Matthew; Wilichowski, Ekkehard; Bryan Burnette, W.; Howard, James F.; McMillan, Hugh J.; Thangarajh, Mathula; Griggs, Robert C.

In: Contemporary Clinical Trials, Vol. 58, 01.07.2017, p. 34-39.

Research output: Contribution to journalArticle

Guglieri, M, Bushby, K, McDermott, MP, Hart, KA, Tawil, R, Martens, WB, Herr, BE, McColl, E, Wilkinson, J, Kirschner, J, King, WM, Eagle, M, Brown, MW, Willis, T, Hirtz, D, Shieh, PB, Straub, V, Childs, AM, Ciafaloni, E, Butterfield, RJ, Horrocks, I, Spinty, S, Flanigan, KM, Kuntz, NL, Baranello, G, Roper, H, Morrison, L, Mah, JK, Manzur, AY, McDonald, CM, Schara, U, von der Hagen, M, Barohn, RJ, Campbell, C, Darras, BT, Finkel, RS, Vita, G, Hughes, I, Mongini, T, Pegoraro, E, Wicklund, M, Wilichowski, E, Bryan Burnette, W, Howard, JF, McMillan, HJ, Thangarajh, M & Griggs, RC 2017, 'Developing standardized corticosteroid treatment for Duchenne muscular dystrophy', Contemporary Clinical Trials, vol. 58, pp. 34-39. https://doi.org/10.1016/j.cct.2017.04.008
Guglieri, Michela ; Bushby, Kate ; McDermott, Michael P. ; Hart, Kimberly A. ; Tawil, Rabi ; Martens, William B. ; Herr, Barbara E. ; McColl, Elaine ; Wilkinson, Jennifer ; Kirschner, Janbernd ; King, Wendy M. ; Eagle, Michele ; Brown, Mary W. ; Willis, Tracey ; Hirtz, Deborah ; Shieh, Perry B. ; Straub, Volker ; Childs, Anne Marie ; Ciafaloni, Emma ; Butterfield, Russell J. ; Horrocks, Iain ; Spinty, Stefan ; Flanigan, Kevin M. ; Kuntz, Nancy L. ; Baranello, Giovanni ; Roper, Helen ; Morrison, Leslie ; Mah, Jean K. ; Manzur, Adnan Y. ; McDonald, Craig M ; Schara, Ulrike ; von der Hagen, Maja ; Barohn, Richard J. ; Campbell, Craig ; Darras, Basil T. ; Finkel, Richard S. ; Vita, Giuseppe ; Hughes, Imelda ; Mongini, Tiziana ; Pegoraro, Elena ; Wicklund, Matthew ; Wilichowski, Ekkehard ; Bryan Burnette, W. ; Howard, James F. ; McMillan, Hugh J. ; Thangarajh, Mathula ; Griggs, Robert C. / Developing standardized corticosteroid treatment for Duchenne muscular dystrophy. In: Contemporary Clinical Trials. 2017 ; Vol. 58. pp. 34-39.
@article{23544dcececf46a394d4eae9c444d37e,
title = "Developing standardized corticosteroid treatment for Duchenne muscular dystrophy",
abstract = "Despite corticosteroids being the only treatment documented to improve strength and function in boys with Duchenne muscular dystrophy (DMD) corticosteroid prescription is inconsistent and in some countries, corticosteroids are not prescribed. We are conducting a clinical trial that (1) compares the 3 most frequently prescribed corticosteroid regimes; (2) standardizes treatment of DMD complications; and (3) standardizes prevention of corticosteroid side effects. Investigators at 38 sites in 5 countries plan to recruit 300 boys aged 4–7 who are randomly assigned to one of three regimens: daily prednisone; daily deflazacort; or intermittent prednisone (10 days on/10 days off). Boys are followed for a minimum of 3 years to assess the relative effectiveness and adverse event profiles of the different regimens. The primary outcome is a 3-dimensional variable consisting of log-transformed time to rise from the floor, forced vital capacity, and subject/parent satisfaction with treatment, each averaged over all post-baseline visits. The study protocol includes evidence- and consensus-based treatment of DMD complications and of corticosteroid side effects. This study seeks to establish a standard corticosteroid regimen for DMD. Since all new interventions for DMD are being developed as add-on therapies to corticosteroids, defining the optimum regimen is of importance for all new treatments.",
keywords = "Deflazacort, Duchenne muscular dystrophy, Prednisolone, Randomized, Standards of care",
author = "Michela Guglieri and Kate Bushby and McDermott, {Michael P.} and Hart, {Kimberly A.} and Rabi Tawil and Martens, {William B.} and Herr, {Barbara E.} and Elaine McColl and Jennifer Wilkinson and Janbernd Kirschner and King, {Wendy M.} and Michele Eagle and Brown, {Mary W.} and Tracey Willis and Deborah Hirtz and Shieh, {Perry B.} and Volker Straub and Childs, {Anne Marie} and Emma Ciafaloni and Butterfield, {Russell J.} and Iain Horrocks and Stefan Spinty and Flanigan, {Kevin M.} and Kuntz, {Nancy L.} and Giovanni Baranello and Helen Roper and Leslie Morrison and Mah, {Jean K.} and Manzur, {Adnan Y.} and McDonald, {Craig M} and Ulrike Schara and {von der Hagen}, Maja and Barohn, {Richard J.} and Craig Campbell and Darras, {Basil T.} and Finkel, {Richard S.} and Giuseppe Vita and Imelda Hughes and Tiziana Mongini and Elena Pegoraro and Matthew Wicklund and Ekkehard Wilichowski and {Bryan Burnette}, W. and Howard, {James F.} and McMillan, {Hugh J.} and Mathula Thangarajh and Griggs, {Robert C.}",
year = "2017",
month = "7",
day = "1",
doi = "10.1016/j.cct.2017.04.008",
language = "English (US)",
volume = "58",
pages = "34--39",
journal = "Contemporary Clinical Trials",
issn = "1551-7144",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Developing standardized corticosteroid treatment for Duchenne muscular dystrophy

AU - Guglieri, Michela

AU - Bushby, Kate

AU - McDermott, Michael P.

AU - Hart, Kimberly A.

AU - Tawil, Rabi

AU - Martens, William B.

AU - Herr, Barbara E.

AU - McColl, Elaine

AU - Wilkinson, Jennifer

AU - Kirschner, Janbernd

AU - King, Wendy M.

AU - Eagle, Michele

AU - Brown, Mary W.

AU - Willis, Tracey

AU - Hirtz, Deborah

AU - Shieh, Perry B.

AU - Straub, Volker

AU - Childs, Anne Marie

AU - Ciafaloni, Emma

AU - Butterfield, Russell J.

AU - Horrocks, Iain

AU - Spinty, Stefan

AU - Flanigan, Kevin M.

AU - Kuntz, Nancy L.

AU - Baranello, Giovanni

AU - Roper, Helen

AU - Morrison, Leslie

AU - Mah, Jean K.

AU - Manzur, Adnan Y.

AU - McDonald, Craig M

AU - Schara, Ulrike

AU - von der Hagen, Maja

AU - Barohn, Richard J.

AU - Campbell, Craig

AU - Darras, Basil T.

AU - Finkel, Richard S.

AU - Vita, Giuseppe

AU - Hughes, Imelda

AU - Mongini, Tiziana

AU - Pegoraro, Elena

AU - Wicklund, Matthew

AU - Wilichowski, Ekkehard

AU - Bryan Burnette, W.

AU - Howard, James F.

AU - McMillan, Hugh J.

AU - Thangarajh, Mathula

AU - Griggs, Robert C.

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Despite corticosteroids being the only treatment documented to improve strength and function in boys with Duchenne muscular dystrophy (DMD) corticosteroid prescription is inconsistent and in some countries, corticosteroids are not prescribed. We are conducting a clinical trial that (1) compares the 3 most frequently prescribed corticosteroid regimes; (2) standardizes treatment of DMD complications; and (3) standardizes prevention of corticosteroid side effects. Investigators at 38 sites in 5 countries plan to recruit 300 boys aged 4–7 who are randomly assigned to one of three regimens: daily prednisone; daily deflazacort; or intermittent prednisone (10 days on/10 days off). Boys are followed for a minimum of 3 years to assess the relative effectiveness and adverse event profiles of the different regimens. The primary outcome is a 3-dimensional variable consisting of log-transformed time to rise from the floor, forced vital capacity, and subject/parent satisfaction with treatment, each averaged over all post-baseline visits. The study protocol includes evidence- and consensus-based treatment of DMD complications and of corticosteroid side effects. This study seeks to establish a standard corticosteroid regimen for DMD. Since all new interventions for DMD are being developed as add-on therapies to corticosteroids, defining the optimum regimen is of importance for all new treatments.

AB - Despite corticosteroids being the only treatment documented to improve strength and function in boys with Duchenne muscular dystrophy (DMD) corticosteroid prescription is inconsistent and in some countries, corticosteroids are not prescribed. We are conducting a clinical trial that (1) compares the 3 most frequently prescribed corticosteroid regimes; (2) standardizes treatment of DMD complications; and (3) standardizes prevention of corticosteroid side effects. Investigators at 38 sites in 5 countries plan to recruit 300 boys aged 4–7 who are randomly assigned to one of three regimens: daily prednisone; daily deflazacort; or intermittent prednisone (10 days on/10 days off). Boys are followed for a minimum of 3 years to assess the relative effectiveness and adverse event profiles of the different regimens. The primary outcome is a 3-dimensional variable consisting of log-transformed time to rise from the floor, forced vital capacity, and subject/parent satisfaction with treatment, each averaged over all post-baseline visits. The study protocol includes evidence- and consensus-based treatment of DMD complications and of corticosteroid side effects. This study seeks to establish a standard corticosteroid regimen for DMD. Since all new interventions for DMD are being developed as add-on therapies to corticosteroids, defining the optimum regimen is of importance for all new treatments.

KW - Deflazacort

KW - Duchenne muscular dystrophy

KW - Prednisolone

KW - Randomized

KW - Standards of care

UR - http://www.scopus.com/inward/record.url?scp=85018333312&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018333312&partnerID=8YFLogxK

U2 - 10.1016/j.cct.2017.04.008

DO - 10.1016/j.cct.2017.04.008

M3 - Article

C2 - 28450193

AN - SCOPUS:85018333312

VL - 58

SP - 34

EP - 39

JO - Contemporary Clinical Trials

JF - Contemporary Clinical Trials

SN - 1551-7144

ER -